The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites.

Muñoz, J. J.; Salamanca, Rafael Enrı́quez de; Diaz-Obregón, C; Timoneda, F. López

doi:10.1111/j.1365-2125.1990.tb03699.x

Cited by 13 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wolf (1985) reported a single case in which CLB considerably raised the levels of CBZ. Munoz et al (1990) studied steady-state metabolite and parent drug plasma ratios in 15 PWE receiving CBZ and seven PWE receiving both CLB and CBZ. CBZ plasma concentrations did not differ between the two groups, but patients also treated with CLB exhibited higher concentrations of the CBZ metabolites CBZ-10,l l-epoxide and trans-l0,l l-dihydro-l0,ll dihydroxy-CBZ, demonstrating that CLB causes a moderate increase (about 1.5-fold) in CBZ metabolism, probably by inducing its epoxidation (Munoz et al, 1990).…”

Section: Pharmacokinetic Studiesmentioning

confidence: 99%

“…Munoz et al (1990) studied steady-state metabolite and parent drug plasma ratios in 15 PWE receiving CBZ and seven PWE receiving both CLB and CBZ. CBZ plasma concentrations did not differ between the two groups, but patients also treated with CLB exhibited higher concentrations of the CBZ metabolites CBZ-10,l l-epoxide and trans-l0,l l-dihydro-l0,ll dihydroxy-CBZ, demonstrating that CLB causes a moderate increase (about 1.5-fold) in CBZ metabolism, probably by inducing its epoxidation (Munoz et al, 1990). Bun et al (1990) monitored the plasma levels of CLB and N-DCLB during chronic treatment of more than 400 PWE receiving a variety of AEDs, as well as in healthy volunteers, investigating the influence of age and AEDs on plasma levels of CLB and N-DCLB.…”

Section: Pharmacokinetic Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The place of clobazam in the treatment of epilepsy: An update

Robertson

1995

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

The 1 ,4-benzodiazepines have a recognized place in the treatment of epilepsy, mainly in status epilepticus, as adjunctive therapy in refractory epilepsy, in hypsarrythmia and in myoclonic epilepsy. Clobazam, the only marketed 1,sbenzodiazepine, has been shown in eight controlled studies involving 291 patients to be significantly superior to placebo, while in 35 open studies embracing 2259 patients, it has produced an overall reduction in seizure frequency of 65 per cent, with some 18 per cent of patients being rendered seizure free. The main indication for its use is as oral adjunctive therapy in refractory epilepsy. It has a rapid onset of action, is well tolerated, and many studies indicate it has a psychotropic action andor produces minimal, or no cognitive impairment. The most common side-effect reported is transient sedation, while the overall incidence of adverse effects in the open studies is 38 per cent. In the controlled investigations 4 per cent of patients had to be withdrawn because of adverse side-effects, while in the open studies the figure was 9 per cent. In general, there are no significant interactions with other antiepileptic drugs, although changes in a few have been described. Withdrawal seizures can occur and require gradual termination of clobazam. The main disadvantage of clobazam is the development of tolerance, which develops in approximately 32 per cent of patients, and there is no way of predicting when the phenomenon is likely to occur nor in which individuals. A dose of 20 to 30mg given preferably at night is recommended, possibly commencing at 10mg.

show abstract

Section: Pharmacokinetic Studiesmentioning

confidence: 99%